Faster drug approvals are not always better and can be worse

JAMA Internal Medicine

Volumn 175, Issue 8, 2015, Pages 1398-

  Redberg, Rita F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ORPHAN DRUG; BIOLOGICAL MARKER;

DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH PRACTITIONER; HUMAN; LIFE EXTENSION; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL; TIME SERIES ANALYSIS; NEOPLASMS; SURVIVAL RATE;

BIOLOGICAL MARKERS; HUMANS; NEOPLASMS; SURVIVAL RATE;

EID: 84939790336     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.2857     Document Type: Editorial

References (3)

1. Prasad V, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses [published online June 22, 2015]. JAMA Intern Med. doi:10.1001/jamainternmed.2015.2829.
2. Energy and Commerce Committee US House of Representatives. Energy and Commerce Cures. http://energycommerce.house.gov/cures. Accessed May 14, 2015.
3. Sanger-Katz M. Speedy drug approvals have become the rule, not the exception [published May 1, 2015]. http://www.nytimes.com/2015/05/02/upshot/speedy-drug-approvals-have-become-the-rule-not-the-exception.html?rref=health&abt=0002&abg=1. Accessed May 19, 2015.